Premium
Hepatic and pancreatic effects of polyenoylphosphatidylcholine in rats with alloxan‐induced diabetes
Author(s) -
Buko Vyacheslav,
Lukivskaya Oxana,
Nikitin Vasily,
Tarasov Yury,
Zavodnik Lev,
Borodinsky Alexandr,
Gorenshtein Bronislava,
Janz Barbara,
Gundermann KarlJosef,
Schumacher Rainer
Publication year - 1996
Publication title -
cell biochemistry and function
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.933
H-Index - 61
eISSN - 1099-0844
pISSN - 0263-6484
DOI - 10.1002/cbf.657
Subject(s) - alloxan , medicine , endocrinology , pancreas , diabetes mellitus , islet , pancreatic islets , insulin
Polyenoylphosphatidylcholine (PPC: 100 or 300 mg kg −1 b.w., by gastric intubation for 30 days) produced a clearcut protection of the liver of rats treated with alloxan (150 mg kg −1 b.w., i.p.). The liver of rats treated with alloxan was characterized by hydropic dystrophy and lymphocytic infiltrations. Treatment with alloxan increased serum γ‐GT and ALAT activities. The liver structure of rats treated with PPC did not differ from the liver of control animals. PPC normalized the biochemical abnormalities caused by the diabetes. The number of pancreatic islets and β/α; cell ratio decreased in the diabetic rats. A number of β‐cells in this group did not contain granules. PPC prevented the decrease in the number of islets and the β/α; cell ratio in the pancreas of the diabetic rats. The intensity of staining of β‐cell granules in the pancreas of PPC‐treated rats had a position intermediate between the control and diabetic groups. Alloxan increased the blood glucose content where treatment with PPC decreased this. The results suggest that PPC acts as a cytoprotector in the liver and pancreas of rats with experimental diabetes induced by alloxan.